Funder
National Institute of Diabetes and Digestive and Kidney Diseases
Cancer Prevention and Research Institute of Texas
Agency for Healthcare Research and Quality
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference33 articles.
1. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer Ver 8. 2020. https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed 4 Dec 2020.
2. Food and Drug Administration. Hematology/Oncology (Cancer) Approvals & Safety Notifications. https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications#:~:text=September%208%2C%202020.,by%20an%20FDA%20approved%20test. Accessed 4 Dec 2020
3. Chen H, Zhao J. KRAS oncogene may be another target conquered in non-small cell lung cancer (NSCLC). Thorac Cancer. 2020;11(12):3425–35.
4. Buajordet I, Ebbesen J, Erikssen J, Brors O, Hilberg T. Fatal adverse drug events: the paradox of drug treatment. J Intern Med. 2001;250(4):327–41.
5. Marcath LA, Coe TD, Hoylman EK, Redman BG, Hertz DL. Prevalence of drug–drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials. BMC Cancer. 2018;18(1):1155.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献